key: cord-0072745-8264n048 authors: Parween, Fauzia; Gupta, Rinkoo Devi title: Insights into the role of paraoxonase 2 in human pathophysiology date: 2022-01-03 journal: J Biosci DOI: 10.1007/s12038-021-00234-7 sha: c68ada245922b1860e9572da6d3b8c27b0543463 doc_id: 72745 cord_uid: 8264n048 Paraoxonase 2 (PON2) is a ubiquitously expressed intracellular enzyme that is known to have a protective role from oxidative stress. Clinical studies have also demonstrated the significance of PON2 in the manifestation of cardiovascular and several other diseases, and hence, it is considered an important biomarker. Recent findings of its expression in brain tissue suggest its potential protective effect on oxidative stress and neuroinflammation. Polymorphisms of PON2 in humans are a risk factor in many pathological conditions, suggesting a possible mechanism of its anti-oxidative property probably through lactonase activity. However, exogenous factors may also modulate the expression and activity of PON2. Hence, this review aims to report the mechanism by which PON2 expression is regulated and its role in oxidative stress disorders such as neurodegeneration and tumor formation. The role of PON2 owing to its lactonase activity in bacterial infectious diseases and association of PON2 polymorphism with pathological conditions are also highlighted. The paraoxonases PON1, PON2, and PON3 are members of esterase family enzymes and are highly conserved within and between species (figure 1) (Teiber et al. 2018) . Phylogenetic analysis has revealed that PON2 is the oldest member of the PON family and that PON1 and PON3 have evolved from it (figure 2) (Draganov and La Du 2004) . The genes of all the three paraoxonases are located next to each other on the long arm of chromosome 7 in the case of humans, and on chromosome 6 in mice (She et al. 2012) . PON1 and PON3 are primarily expressed in the liver, and get associated with high density lipoprotein (HDL), whereas PON2 is ubiquitously expressed and is not present in the blood plasma (Ng et al. 2001; Kulka 2016) . PON2 has been detected in several tissues at mRNA level, protein level, or both, including the brain where the other two PONs are not expressed (Costa et al 2014; Ng et al. 2001; Giordano et al. 2011) . The highest levels of PON2 are expressed in the lungs and small intestine, followed by the heart and liver, whereas lower levels are reported in testis, kidney, and brain (Marsillach et al. 2008) . Although the name 'PON' suggests Four mammals were selected randomly, and their sequences were retrieved from NCBI. Sequence alignment and phylogenetic tree construction were done by using Clustal Omega. The scores on the tree correspond to the evolutionary distance between the sequences. Bacchetti et al. (2017) paraoxonase but PON2 and PON3 have almost no paraoxonase activity (Draganov et al. 2005) . Only PON1 has a weak paraoxonase activity, but all the three PONs exhibit anti-oxidant and anti-inflammatory activities. Their physiological function(s) and native substrates, however, remain ambiguous (Richter et al. 2009; Grdic Rajkovic et al. 2011) . The native enzyme activity of paraoxonases was found to be lactonase, suggesting that despite its promiscuous nature the endogenous substrates of paraoxonases are lactones (Draganov et al. 2005) . Subcellular localization studies of PON2 show that it is particularly present at the perinuclear region, endoplasmic reticulum (ER), and mitochondria (Horke et al. 2007 ). At the plasma membrane level, PON2 is a transmembrane protein with its enzymatic domain facing the extracellular compartment, and thus plays an important role in rescuing peroxidation of membrane components (Hagmann et al. 2014) . Mitochondria are cytoplasmic organelles whose integrity is essential for maintaining specific physiological, biochemical, and morphological features of cells. They, therefore, play an essential role in the life and death of the cells (Rasheed et al. 2017) . The fact that PON2 is located in mitochondria suggests its anti-oxidative nature, and thus its cytoprotective role. Therefore, PON2 deficiency causes mitochondrial dysfunction in these cells (Devarajan et al. 2011) . In addition to its antioxidant activity, PON2 has a remarkably high lactonase activity as compared to PON1 and PON3 (Teiber et al. 2008) . The lactonase activity of PON2 may be responsible for its anti-inflammatory role. It was reported in the intestinal epithelial cells that PON2 silencing exacerbated inflammatory processes thereby disturbing the mucosal integrity (Précourt et al. 2012 ). However, a mutant PON2 (PON2-As-n254Ala/Asn323Ala) lacking lactonase activity does not affect the anti-inflammatory functions (Stoltz et al. 2009 ). In vivo studies also suggest that PON2 knocked out mice has exacerbated macrophage inflammatory response (Ng et al. 2006 ). The mechanism by which PON2 accomplishes anti-inflammatory function is poorly understood mainly due to the lack of its targets or substrates in physiological conditions. Association of PON2 with coenzyme Q and preventing reactive oxygen species (ROS) generation in mitochondria is irrespective of its lactonase activity (Altenhöfer et al. 2010; Devarajan et al. 2014) . These observations suggest that the antioxidative nature of PON2 might be independent of its lactonase activity. PON1 has been well studied as compared to PON2 and PON3, and recently evolved for the stereospecific hydrolysis of G-type of nerve agents (Gupta et al. 2011) . However, PON2 is emerging as an important defense system owing to its location, expression, and significant lactonase activity. The protective role of PON2 has been well documented in vascular, neuronal, macrophage, and other cells against oxidative stress as the downregulation of PON2 was found to be antagonizing its protective effect (Schweikert et al. 2012b ). Reportedly, PON2 overexpression prevents ER and/or oxidative stress (Horke et al. 2007) . Several chronic diseases develop due to elevated levels of ROS. Therefore, understanding the role of PON2 in scavenging cellular ROS can be an important finding. Although, the cytoprotective role of PON2 is well established, the mechanism by which it reduces ROS and thereby apoptosis, is not well understood (Witte et al. 2012) . Therefore, efforts are being made to understand the associated signaling pathways and their pathophysiological relevance (Devarajan et al. 2018) . It would be of many benefits to studying PON2 overexpression and its contribution to cancer as it confers apoptosis resistance (Horke et al. 2008; Witte et al. 2011) . Moreover, PON2 is attracting significant interest due to its expression in the nervous system and its role in preventing neurodegeneration (Giordano et al. 2011) . Here, we have described the enigmatic role of PON2 in molecular physiology and redox homeostasis, and how the modulation of its expression could be a therapy for several diseases. Owing to the pathophysiological role of PON2 in several diseases, strategies attempting to modulate its level of expression could have important health implications. In this regard, several bioactive molecules are known to regulate PON2 expression and activity, which are discussed below in details. PON2 gene transcription is regulated in an integrated multistep pathway. PON2 expression is under genetic control and regulated by cellular oxidative stress as well as by cholesterol content (Rosenblat et al. 2004; Shiner et al. 2006) . Low transcriptional activity of PON2 has been recognized as one of the major culprits in recurrent abortion due to its inadequate antioxidative defense (Dikbas et al. 2018) . Several transcription factors such as peroxisome proliferatoractivated receptor c (PPARc), sterol regulatory element-binding protein 2(SREBP-2), and activator protein-1 (AP-1) activation are known to upregulate PON2 expression. Reportedly, stimulating macrophages with urokinase activates phosphoinositide 3-kinase (PI3K) through platelet-derived growth factor ß which further activates NADPH oxidase resulting in the production of ROS, which is ultimately involved in the regulation of PON2 expression (Shiner et al. 2007a, b; Fuhrman et al. 2009 ). More recently, two new transcription factors, Wilms tumor 1 associated protein (WTAP) and the baculoviral IAP repeat-containing 3 (BIRC3) are shown to modulate PON2 expression and activity (Carusone et al. 2020) . Furthermore, it was demonstrated that the glucocorticoidglucocorticoid receptor complexes are directly involved in the transactivation of AP-1 which is responsible for transcriptional activation of the PON2 gene (Shiner et al. 2004 (Shiner et al. , 2007a . Contradictorily, some findings suggest the role of the glucocorticoid receptor in directly regulating PON2 expression irrespective of AP-1 (Lim and Kim 2009 ). These findings indicate that cellular PON2 expression has a direct or indirect role in signaling pathways associated with ROS production and cholesterol biosynthesis (Fuhrman et al. 2009 ). Epigenetic regulation of PON1 has also been established (Huen et al. 2015; Mahrooz et al. 2019) ; however, the epigenetic regulation of PON2 and PON3 are not studied well (Holland et al. 2015; Mahrooz and Mackness 2020) . Xiao et al. showed that PON2 had very little methylation as compared to PON1 and PON3 in case of patients with cerebral infarction and control ). Hormonal regulation of PON2 has been very-well investigated, where sex steroids have gained much attention (Giordano et al. 2011; Siddiqui et al. 2016 ). This could be useful to understand the etiology of various neurodegenerative disorders as PON2 levels are higher in central nervous system tissues that is the brain and peripheral region of female mice than male mice (Costa et al. 2014). The lower expression of PON2 in males as compared to females may have wider consequences for the predisposition to oxidative stress diseases. This includes neurodegenerative diseases such as Alzheimer's, Parkinson's, cardiovascular diseases as well as Covid-19, where males are more susceptible to the disease than females (Liguori et al. 2018; Levy et al. 2019; Jin et al. 2020) . For example, the incidence of Parkinson's disease is 90% higher in males as compared to female (Wirdefeldt et al. 2011; Costa et al. 2014) , suggesting that the higher PON2 levels in dopaminergic neurons of females may provide better protection against oxidative stress (Giordano et al. 2011 (Giordano et al. , 2013 . The gender difference in PON2 expression levels may be attributed to the positive modulatory effect of estrogens in female mice (Leranth et al. 2000; Kitamura et al. 2009; Bwire 2020) . Estradiolinduced increase in PON2 mRNA, as well as protein levels, in a time-and concentration-dependent manner, in both male and female striatal astrocytes, is probably due to the activation of estrogen receptoralpha. Similarly, in ovariectomized female mice, it was observed that PON2 mRNA and protein levels decreased as compared to that in a male in brain regions and liver (Cheng and Klaassen 2012; Giordano et al. 2013) . Interestingly, some plant hormones also have a modulatory effect on PON2 expression. Glabridin, the licorice phytoestrogen, has been found to increase PON2 expression, and protects its activity. Glabridin interacts with PON2, and prevents its oxidation, thus preserving its activity, in hyperglycemic patients (Yehuda et al. 2011) . Furthermore, as PON2 is expressed ubiquitously in all tissues, and the levels of expression is more or less higher in females in each tissues examined, the reported higher sensitivity of males to oxidative stress in the brain, the heart, the kidney, or the liver may be related to the similar mechanism (Klein 2000; Valle et al. 2007 ). PTMs take place either on the amino acid side chains or at the C-or N-termini of PON2 protein, thereby regulating its catalytic activity. There are contradictory studies on the dependence of PON2 enzyme activity on N-glycosylation. Ser311Cys polymorphism or ubiquitination at Lys168 have been found to modulate PON2 activity (Mandrich et al. 2015) . Amino acid substitution at position 311 from serine to cysteine in recombinant PON2 altered glycosylation, and decreased lactonase activity but protein production and localization are normal (Stoltz et al. 2009 ). Likewise, studies are pointing to side-chain modification of amino acid residues regulating the catalytic activity of PON2. Carusone et. al. found that N-(3-oxododecanoyl)-L-homoserine lactone (3OC12-HSL) induced post-translational modification at multiple positions in PON2. For instance, posttranslational modification at position 144, nearby two SNPs (A148G and S311C) has been shown to affect PON2 activity (Carusone et al. 2020 ). Commonly used NSAIDs are reported to affect PON2 specific lactonase and arylesterase activity. NSAIDs, like diclofenac sodium and tenoxicam, have been tested in vitro, causing a significant decline in lactonase activity (Solmaz Avcıkurt and Korkut 2018). On the other hand, antenatal steroid therapy did not affect PON2 mRNA expression in placentae of unexplained intrauterine growth restricted pregnancies as compared to the non-treated group (Dikbas et al. 2017) . It is also hypothesized that increased cholesterol content may be the cause of decreased PON2 expression (Rosenblat et al. 2004) . Therefore, hypocholesterolemic drugs may prove to be positive modulators of PON2. One such drug, atorvastatin, has been reported to upregulate PON2 expression in various cell types (Shiner et al. 2007b ). Dietary factors including flavonoids and polyphenols have long been known to possess antioxidant properties, and modulate intracellular antioxidant enzymes. The underlying molecular mechanisms by which flavonoids may induce PON2 gene expression have not been fully elucidated (Pandey and Rizvi 2009; Costa et al. 2016) . Flavonoids from pomegranate are reported to affect the DNA binding activity of the transcription factor AP-1, which is present in the promoter region of the PON2 gene (Shiner et al. 2007a) . It is also proposed that increasing concentrations of plant polyphenol, quercetin, in murine macrophages resulted in upregulated PON2 at mRNA as well as protein levels (Boesch-Saadatmandi et al. 2009 ). PON2 gene is partly regulated by NADPH oxidase, which is a molecular target of quercetin (Shiner et al. 2004) . Chlorogenic acid, a major phenolic compound of Yerba mate, a plant species consumed as traditional tea, could increase the relative expression of PON2 mRNA as well as enzyme activity in vitro in macrophages. On the other hand caffeic acid, a metabolite of chlorogenic acid in the plasma, did not affect PON2 gene expression, but increased its enzyme activity at an appropriate concentration (Monteiro et al. 2007; Fernandes et al. 2012) . Eicosapentaenoic acid (EPA) is a long-chain omega-3 polyunsaturated fatty acid that was investigated for its cardioprotective property. EPA administration increased HDL cholesterol, decreased fasting blood sugar, and upregulated PON2 gene expression in patients with type 2 diabetes mellitus (Endo and Arita 2016; Golzari et al. 2019). More recently, higher glucose concentration as compared to physiological levels was found to downregulate PON2. The formation of advanced glycation end products is induced by elevated glucose levels. In human umbilical vein endothelial cells (HUVECs), overexpression of PON2 reduced both the early and the late glycation end products, induced ROS, ER stress, and inflammation (Morresi et al. 2019; Ravi et al. 2020) . Negative modulation of PONs, especially PON1, is also reported for several metals, and vice-versa susceptibility to toxicity and neurotoxicity of metals is affected by different levels of PONs (Costa et al. 2017). Therefore, pharmacological, dietary, lifestyle, and environmental factors modulating PON2 could be considered as important factors for the prevention and cure of several diseases. Certain modulators of PON2 are broadly classified and summarized in table 2. Several studies in the recent years have confirmed the overexpression of PON2 in cancerous cells. Reportedly, PON2 could be involved in tumor survival and stress resistance. An elaborate clinical study, conducted on tumor samples taken from more than 10,000 patients with different types of cancer, showed a high expression of PON2 in multiple types of solid tumors, suggesting that overexpression of PON2 in cancer cells causes resistant to chemotherapy and other unfavorable conditions causing malignancy (Shakhparonov et al. 2018) . Similarly, overexpression of PON2 in bladder cancer cell lines led to a significant increase in cell proliferation and resistance to oxidative stress (Bacchetti et al. 2017) . More recently, a study reported PON2 as an oncogene in gastric cancer, overexpression of which was correlated to tumor diffusion and invasion . Therefore, it is suggested that PON2 can be used as molecular biomarker for the prognosis of multiple types of cancer (Bacchetti et al. 2021; Campagna et al. 2020) . The fact that PON2 helps in apoptotic escape represents a major clinical complication in cancer biology. However, the distinct regulatory pathways are poorly understood. Both PON2 and PON3 are involved in modulating mitochondrial superoxide anion production and ER stress-induced apoptosis (Bacchetti et al. Another theory put forward for the anti-apoptotic role of PON2 is that p53 transcriptionally represses PON2, and in case of any mutation in p53, there is overexpression of PON2 (figure 3). PON2 was shown to be overexpressed in pancreatic cancer tissues i.e. pancreatic ductal adenocarcinoma where mutations in TP53 are present which facilitate the metastatic progression (Nagarajan et al. 2017) . Along with PON2, other factors like Hypoxia-Inducible Factor-1 (HIF 1) may also come into play, and support tumor progression through multiple pathways (Amelio et al. 2018) . It is also reported that PON2 positively modulates the expression of Glucose Transporter 1 (GLUT 1), and thus inhibits the AMP-activated protein kinase (AMPK) pathway (Nagarajan et al. 2017; Pan et al. 2019) . AMPK pathway of apoptosis functions in response to cellular starvation in normal cells, and serves as a possible metabolic tumor suppressor (Li et al. 2015) . As PON2 overexpression causes an increase in GLUT 1 expression, there is more and more glucose intake, which shuts down the AMPK pathway. Therefore, by inhibiting the AMPK pathway PON2 stabilizes the tumor. This is very similar to Warburg's phenomenon suggesting aerobic glycolysis where glucose is used for various biosynthetic pathways that promote cell proliferation (Faubert et al. 2013; Hu et al. 2019) . Moreover, PON2 counteracts lipid peroxidation, which may add to stabilizing tumor cells. For example, PON2 attenuates cardiolipin peroxidation in the mitochondrial membrane to prevent intrinsic apoptosis (Witte et al. 2011) . In yet another study, regulation of PON2 protein expression through the Wnt/GSK3b/b-catenin pathway in leukemia and oral squamous cell cancer (OSCC) was demonstrated (Krüger et al. 2016) . In OSCC, the anti-apoptotic nature of PON2 was correlated with resistance to radiotherapy (Krüger et al. 2015) . PON2 overexpression in bladder cancer cells is also shown to resist chemotherapy by counteracting the induced ROS due to its antioxidative property (Fumarola et al. 2020). In the case of ovarian cancer, it was noticed that PON2 expression was enhanced in the early stages of cancer but at later stages, there was no change in the expression. This might be because PON2 regulates tumorigenesis in a Spatio-temporal manner (Devarajan et al. On the other hand, PON2 may also be indirectly involved in tumorigenesis via Reperfusion Injury Salvage Kinase (RISK) pathway. PON2 reduces cardiolipin peroxidation, cytochrome C release, and activation of caspase (figure 3) (Sulaiman et al. 2019a, b) . Downregulation of PON2 may be important in targeting cancer. According to a report, valproic acid stimulation led to a decrease in PON2 expression in glioblastoma multiforme cells. This in turn inhibited cancer progression by increasing ROS production which ultimately promoted apoptosis via the Bim cascade (Tseng et al. 2017) . Unlike PON1 and PON3 that remain associated with HDL, and perform an anti-oxidative function, PON2 appears to be present in endothelial cells, smooth muscle cells, and macrophages where it remains associated with membranes of ER and nucleus She et al. 2012) . The cardioprotective role of PON2 is shown in both experimental and human heart failure. This may be attributed to significantly increased PON2 activity, its ability to improve mitochondrial function, and diminish ROS generation (Li et al. 2018) . Recent studies have shown that in endothelial cells, PON2 prevents systemic coagulation and inflammation by regulating the activity of tissue factors by a redox-dependent mechanism (Ebert et al. 2018). In rats with hemorrhagic shock, it was found that under hypoxic and ischaemic conditions, PON2 regulates the expression of endothelial tissue-related genes such as plasma thrombomodulin transcription factors and endothelial tissue factor activating the mechanism of coagulation (Xu et al. 2020) . Oxidative stress is one of the main causes of atherosclerosis. Hydrolysis of peroxidized lipid is one of the important functions that may contribute to the cardio-protective nature of PON2 (Hagmann et al. 2014 ). An in vivo study demonstrated that PON2 prevents the oxidation of lipoprotein, thus enhancing the protective capacity of HDL and reducing the intracellular oxidative stress levels of macrophages (Chen et al. 2016) . The RISK pathway, PI3K/Akt/ GSK-3b (figure 3C), is cardioprotective against Ischemia-Reperfusion Injury (IRI), PON2 reportedly activates the pathway and therefore prevents mitochondrial dysfunction, and hence oxidative stress in cardiomyocytes (Sulaiman et al. 2019a, b) . Apart from cholesterol, triglycerides are also independent risk factors for atherosclerosis, and diacylglycerol acyltransferase 1 (DGAT1) is a rate-limiting enzyme in the triglyceride biosynthetic pathway (Lundberg 1985; Farese et al. 2000) . Rosenblat et. al. found that PON2 increases DGAT1 activity, and thus the rate of triglyceride formation. Therefore, one of the mechanisms of the protective role of PON2 in atherosclerosis may be attributed to its regulatory effect on DGAT1 activity which is sensitive to oxidative stress (Rosenblat et al. 2009 ). But in the case of pro-atherogenic infection, the anti-atherogenic activity of PON2 was attributed to its ability to destroy quorum sensing molecule which is due to the lactonase activity of the enzyme (Kim et al. 2011) . The pro-atherogenic infection is contributed by quorum sensing molecules, such as N-(3-oxododecanoyl)-L-homoserine lactone (3OC12-HSL) of Pseudomonas aeruginosa (Turkay et al. 2004) . The role of PON2 was also pointed out in obesity. It was found that PON2 deficient mice had altered mitochondrial function in white adipose tissue which further prevented its conversion to brown adipose tissue, and hence contributed to diet-induced obesity (Shih et al. 2019) . A comparative in vivo and in vitro study in type 2 diabetes patients showed a significant decrease in PON2 enzyme activity in monocyte/macrophage cells (Lixandru et al. 2017) . It was correlated to abdominal obesity and insulin resistance (Qujeq et al. 2018) . However, the underlying molecular mechanisms remain unrecognized. Owing to the hydrolytic activity of PON2, it has a crucial role in infectious diseases and associated anomalies such as oxidative stress, inflammation, and changes in the serum proteins (Camps et al. 2017) . Studies show that PON2-deficient mice are more prone to bacterial infections than wild-type mice (Stoltz et al. 2007) . The role of PON2 in cutaneous defense against bacterial infections due to its high level of expression and activity in human keratinocytes is also reported (Simanski et al. 2012) . Most gram-negative bacteria use lactones as quorum sensing (QS) molecules (Rutherford and Bassler 2012). Hydrolytic activity, mainly lactonase activity of PON2, is responsible for the control of QS in gram-negative bacteria such as P. aeruginosa, therefore offering an important defense mechanism against bacterial infections (figure 4) (Farid and Horii 2012). PON2 hydrolyzes and inactivates certain homoserine lactones (HSL), and therefore attenuates HSL mediated immune responses (Teiber et al. 2008; Devarajan et al. 2013) . Thus, PON2 plays a pivotal role in regulating host cell responses to QS molecules by decreasing their availability for receptor-mediated effects such as calcium release and stress signaling (Horke et al. 2015) . The quorum quenching ability of PON2 is also associated with lung pathophysiology of cystic fibrosis (CF) patients. PPAR c is a mammalian anti-inflammatory transcription factor that is inhibited by 3OC12-HSL (Jahoor et al. 2008) . Studies suggest that P. aeruginosa infected CF patients have reduced expression of PPAR c and PON2 genes (Griffin et al. 2012). Therefore, PON2 has been found to play a crucial role in defense against infectious diseases. Moreover, the role of PON2 in the case of innate immune response to viral infection is also elucidated. In vitro and in vivo studies have shown an increase in PON2 gene expression, protein levels, and activity in response to HIV-1 infection which may be attributed to dephosphorylation of Signal transducer and activator of transcription 5 (STAT5) (Yuan et al., 2010) . PON2 has been identified as a novel and major intracellular factor with an antagonizing role in oxidative stress in the central nervous system (Costa et al. 2014) . It is an intracellular protein, localized on the inner mitochondrial membrane and bound to Coenzyme Q 10 , a major site for the generation of ROS. PON2 sequesters unstable coenzyme Q during the Q cycle and prevents it from passing electrons to oxygen molecules instead of cytochrome C. Its absence or deficiency causes redox imbalance and reduced electron transport activity. It may thus contribute to mitochondrial dysfunction and various oxidative stress disorders Dopaminergic regions of the brain have the highest levels of PON2. There is also evidence that suggests the expression of PON2 is higher in astrocytes than in neurons (Giordano et al. 2011) . In an experiment on the study of PON2 levels in the brain during development, the highest expression levels were detected in premature mice with a gradual decline in aged mice. The authors attributed significantly high levels of PON2 in early brain development to its role in protecting brain cells from oxidative stress during the developmental stages As higher PON2 levels are associated with increased resistance to oxidative stress-induced toxicity and neuroinflammation in brain cells, the possibility of modulating PON2 levels in neuronal cells may represent a much beneficial neuroprotective strategy (Costa et al. 2013) . Reportedly, quercetin, a plant flavonoid, helps in mitigating ROS in PON2 ?/? mice better than in PON2 -/mice and thus has an ameliorating effect on Alzheimer's disease (AD) (Khan et al. 2020) . Though, several hypotheses for the neuroprotective mechanism of quercetin have been put forward yet the exact mechanism is elusive. Either the quercetin induces a low level of oxidative stress and induces PON2 expression through JNK/AP-1 pathway or due to its phytoestrogen activity, PON2 expression is induced (Ruotolo et al. 2014; Costa et al. 2016) . The role of PON2 in Parkinson's disease (PD) was speculated recently. A study reports that DJ 1, a gene responsible for PD, interacts with PON2 and is neuroprotective in the PD model (Parsanejad et al. 2014) . However, in the case of MPP ? (1-methyl-4phenylpyridinium) induced PD model, lovastatin has a neuroprotective function irrespective of PON2 (Aguirre-Vidal et al. 2015) . Apparently, the overexpression of PON2 is cytoprotective, however, its implications can be different depending on the type of cells, for instance, PON2 overexpression is neuroprotective, however, in case of tumor cells the cytoprotective nature of PON2 may inhibit apoptosis and help in cancer progression. Two common polymorphisms of PON2 are found, Ala/ Gly at position 148 and Ser/Cys at position 311 (Mochizuki et al. 1998) . A few studies are present which demonstrate the relationships of these two PON2 polymorphisms with different pathophysiological conditions (table 3) (Shin 2009; Elnoamany et al. 2014) . PON2 Ser311Cys polymorphism has been associated with cardiovascular disease (CVD) but there are still controversies regarding it. Some findings claim that Ser at 311 is more at risk of developing CVD, whereas Cys at 311 prevents premature development of CVD (Martinelli et al. 2004; Chen et al. 2016 ). On the other hand, few studies report that there is not much significant change between these two polymorphic forms (Sanghera et al. 1998 ). Therefore, more functional studies need to be carried out for PON2 Ser311Cys polymorphism and its relationship with CVD. More recently, it has been reported that polymorphism at Ser311Cys is responsible for interaction with another gene PPAR ! , and polymorphic forms of both the gene can serve as biomarkers of risk for coronary heart disease (González-Castro et al. 2018) . PON2 Cys311Ser polymorphism is also linked with AD. PON2 311Ser along with another gene apoE4 allele helps in the development of AD and vascular dementia (Janka et al. 2002; Nie et al. 2017) . The Cys allele of Cys311Ser polymorphism is associated with sporadic Amyotrophic Lateral Sclerosis (ALS) (Saeed et al. 2006; Slowik et al. 2006 ). Valdmanis et. al. conducted a study on French, Canadian and Swedish population, and found that Cys311Ser polymorphism in PON2 was relevant risk factor for the development of ALS irrespective of patients' nationality (Valdmanis et al. 2008 ). On the other hand Cys311Ser PON2 polymorphism was not associated with ALS in Italian population (Ricci et al. 2011) . Although PON1/3 are not expressed in the brain, polymorphisms in these are associated with Sanghera et al. (1998) Gly 148 and Ser 311 Cataract Baig et al. (2019) neurodegenerative conditions, possibly via regulatory aspects of lipid metabolism (apolipoproteins) (Reichert et al. 2021) . Activity and expression level may be associated with PON polymorphism and neurodegeneration. All the PONs can hydrolyze oxidized form of lipids whereas PON1 has in addition organophosphatase activity ( Recently, the association of PON2 polymorphism has been demonstrated in the metabolism of acetylcholinesterase inhibiting drugs (AChEI) such as donepezil hydrochloride and pyridostigmine bromide. The polymorphic forms of PON2, Ala/Gly at position 148 and Ser/Cys at position 311, showed different arylesterase activity, and thus responded differently to these drugs. PON2 with Gly148 and Cys311 allele had increased arylesterase activity, and also the enzyme became more efficient in inhibiting the drug in these cases. The arylesterase activity of PON2 could be responsible for the hydrolysis of AChEI used against AD and thus attenuating the efficacy of these drugs (Parween et al. 2021) . PON2 has emerged as an important cellular antioxidant against oxidative stress, mainly due to its expression in several tissues and additionally mitochondrial localization. This lactonase enzyme has shown the potential of being an important biomarker as it plays a relevant role in determining susceptibility to oxidative stress and neuroinflammation. Its overexpression may provide a novel strategy for neuroprotection, whereas in tumor cells a useful therapeutic strategy would be helpful in lowering the expression of PON2. A lower rate of occurrence of a wide variety of diseases such as Alzheimer's, Parkinson's, and CVD in females as compared to males suggests that attempts aimed at increasing the PON2 level of expression in males might be useful. Deciphering the mechanism of PON2 upregulation will also provide useful insights into the pathophysiology of several diseases and thus a therapeutic lead due to its multifaceted role (figure 6). In general, the increase of PON2 activity was associated with gene transcription. The upregulation of PON2 might therefore occur through the stabilization of the PON2 protein or due to its overexpression through an increased translation rate. The kind of cellular signaling pathways that distinct phenolic compounds activate, and the structure and concentration of phenolic compounds themselves also determine the regulation of PON2 activity. Further, understanding the associations of PON2 polymorphism with pathophysiological conditions and drug metabolism would be advantageous for the development of future precision medicines. However, additional studies need to be performed to explain the mechanisms of action of these modulators in the regulation of gene expression and activity. The neuroprotective effect of lovastatin on MPP?-induced neurotoxicity is not mediated by PON2 One enzyme, two functions: PON2 prevents mitochondrial superoxide formation and apoptosis independent from its lactonase activity p53 mutants cooperate with HIF-1 in transcriptional regulation of extracellular matrix components to promote tumor progression Paraoxonase-2: a potential biomarker for skin cancer aggressiveness The role of paraoxonase in cancer Exploring the role of Paraoxonase-2 in bladder cancer: analyses performed on tissue samples, urines and cell culturess Association of PON2 and PON3 polymorphism with risk of developing cataract Pioglitazone activates paraoxonase-2 in the brain: a novel neuroprotective mechanism Effect of quercetin on paraoxonase 2 levels in RAW264. 7 macrophages and in human monocytes-role of quercetin metabolism Coronavirus: why men are more vulnerable to Covid-19 than women? SN Compr Paraoxonase 2 (PON2) polymorphisms and development of renal dysfunction in type 2 diabetes: UKPDS 76 Paraoxonase-2 silencing enhances sensitivity of A375 melanoma cells to treatment with cisplatin Paraoxonases and infectious diseases Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in Gramnegative bacteria 2020 WTAP and BIRC3 are involved in the posttranscriptional mechanisms that impact on the expression and activity of the human lactonase PON2 Myeloperoxidase, paraoxonase-1, and HDL form a functional ternary complex PON1 as a model for integration of genetic, epigenetic, and expression data on candidate susceptibility genes Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer Codon 311 (Cys? Ser) polymorphism of paraoxonase-2 gene is associated with apolipoprotein E4 allele in both Alzheimer's and vascular dementias Gender differences in patients with COVID-19: focus on severity and mortality Neuroprotective effects of quercetin in Alzheimer's disease Paraoxonase-2 modulates stress response of endothelial cells to oxidized phospholipids and a bacterial quorum-sensing molecule Beneficial effects of estrogen in a mouse model of cerebrovascular insufficiency The effects of hormones on sex differences in infection: from genes to behavior The anti-apoptotic PON2 protein is Wnt/b-catenin-regulated and correlates with radiotherapy resistance in OSCC patients Paraoxonase-2 (PON2) protects oral squamous cell cancer cells against irradiation-induced apoptosis A review of paraoxonase 1 properties and diagnostic applications Estrogen is essential for maintaining nigrostriatal dopamine neurons in primates: implications for Parkinson's disease and memory Paraoxonases activities and polymorphisms in elderly and old-age diseases: an overview Paraoxonase 2 prevents the development of heart failure. Free Radic Targeting AMPK for cancer prevention and treatment Oxidative stress, aging, and diseases Transcriptional activation of an anti-oxidant mouse Pon2 gene by dexamethasone Decreased paraoxonase 2 enzymatic activity in monocyte/macrophages cells. A comparative in vivo and in vitro study for diabetes Chemical composition and physical state of lipid deposits in atherosclerosis Human paraoxonase-1 (PON1): gene structure and expression, promiscuous activities and multiple physiological roles Epigenetics of paraoxonases The epigenetic regulation of paraoxonase 1 (PON1) as an important enzyme in HDL function: the missing link between environmental and genetic regulation An engineered version of human PON2 opens the way to understand the role of its post-translational modifications in modulating catalytic activity Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Free Radic Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction Human PON2 gene at 7q21. 3: cloning, multiple mRNA forms, and missense polymorphisms in the coding sequence Chlorogenic acid compounds from coffee are differentially absorbed and metabolized in humans Effect of high glucose-induced oxidative stress on paraoxonase 2 expression and activity in Caco-2 cells Paraoxonase 2 facilitates pancreatic cancer growth and metastasis by stimulating GLUT1-mediated glucose transport Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: antiatherogenic role for paraoxonase-2 Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cellmediated oxidative modification of low density lipoprotein A meta-analysis on the relationship of the PON genes and Alzheimer disease Paraoxonases gene expression and distribution in rats organs treated with atherogenic diet and atorvastatin therapy Paraoxonase 2 enables initiation of B-ALL by subverting metabolic gatekeeper functions Plant polyphenols as dietary antioxidants in human health and disease. Oxidative medicine and cellular longevity DJ-1 interacts with and regulates paraoxonase-2, an enzyme critical for neuronal survival in response to oxidative stress Association between human paraoxonase 2 protein and efficacy of acetylcholinesterase inhibiting drugs used against Alzheimer's disease Antioxidative properties of paraoxonase 2 in intestinal epithelial cells The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family Paraoxonase-2 variants potentially influence insulin resistance, beta-cell function, and their interrelationships with alanine aminotransferase in type 2 diabetes Mitochondrial permeability transition pore: a promising target for the treatment of Parkinson's disease Effect of advanced glycation end product on paraoxonase 2 expression: its impact on endoplasmic reticulum stress and inflammation in HUVECs Paraoxonase role in human neurodegenerative diseases Lack of association of PON polymorphisms with sporadic ALS in an Italian population Paraoxonase 1 (PON1) status and substrate hydrolysis Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart study II Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1 Decreased macrophage paraoxonase 2 expression in patients with hypercholesterolemia is the result of their increased cellular cholesterol content: effect of atorvastatin therapy Glucuronidation does not suppress the estrogenic activity of quercetin in yeast and human breast cancer cell model systems Bacterial quorum sensing: its role in virulence and possibilities for its control. Cold Spring Harb Paraoxonase cluster polymorphisms are associated with sporadic ALS Gonadotropin-mediated chemoresistance: delineation of molecular pathways and targets DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease Upregulation of BiP and CHOP by the unfolded-protein response is independent of presenilin expression PON3 is upregulated in cancer tissues and protects against mitochondrial superoxide-mediated cell death Paraoxonases-2 and-3 are important defense enzymes against Pseudomonas aeruginosa virulence factors due to their anti-oxidative and antiinflammatory properties Expression and intracellular localization of paraoxonase 2 in different types of malignancies The human paraoxonase gene cluster as a target in the treatment of atherosclerosis PON2 deficiency leads to increased susceptibility to diet-induced obesity The roles of PON1 and PON2 in cardiovascular disease and innate immunity Paraoxonase gene polymorphism in southwestern Korean population Paraoxonase 2 (PON2) expression is upregulated via a reduced-nicotinamide-adenine-dinucleotide-phosphate (NADPH)-oxidase-dependent mechanism during monocytes differentiation into macrophages. Free Radic A biphasic U-shape effect of cellular oxidative stress on the macrophage anti-oxidant paraoxonase 2 (PON2) enzymatic activity Macrophage paraoxonase 2 (PON2) expression is up-regulated by pomegranate juice phenolic anti-oxidants via PPARc and AP-1 pathway activation Macrophage paraoxonase 2 (PON2) expression is upregulated by unesterified cholesterol through activation of the phosphatidylinositol 3-kinase (PI3K) pathway Neuroprotective role of steroidal sex hormones: an overview Paraoxonase 2 acts as a quorum sensing-quenching factor in human keratinocytes Paraoxonase gene polymorphisms and sporadic ALS Effect of certain non-steroidal anti-inflammatory drugs on the paraoxonase 2 (PON2) in human monocytic cell line U937 Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia A common mutation in paraoxonase-2 results in impaired lactonase activity Paraoxonase 2 protects against acute myocardial ischemia-reperfusion injury by modulating mitochondrial function and oxidative stress via the PI3K/Akt/ GSK-3b RISK pathway The role of paraoxonase 2 (PON2) in mitochondrial membrane phospholipid composition and lipid peroxidation The structure and function of paraoxonase-1 and its comparison to paraoxonase-2 and-3 Identification of biologically active d-lactone eicosanoids as paraoxonase substrates Dominant role of paraoxonases in inactivation of the Pseudomonas aeruginosa quorum-sensing signal N-(3-oxododecanoyl)-L-homoserine lactone tissue Tissue expression of PON2 -Summary -The Human Protein Atlas Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression Effect of chronic Pseudomonas aeruginosa infection on the development of atherosclerosis in a rat model Association of paraoxonase gene cluster polymorphisms with ALS in France Sexual dimorphism in liver mitochondrial oxidative capacity is conserved under caloric restriction conditions The role of the ER-induced UPR pathway and the efficacy of its inhibitors and inducers in the inhibition of tumor progression Association of paraoxonase gene polymorphisms with diabetic nephropathy and retinopathy The clinical and prognostic significance of paraoxonase-2 in gastric cancer patients: immunohistochemical analysis Epidemiology and etiology of Parkinson's disease: a review of the evidence Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells Protectors or traitors: the roles of PON2 and PON3 in atherosclerosis and cancer PON1 hypermethylation and PON3 hypomethylation are associated with risk of cerebral infarction Molecular mechanism whereby paraoxonase-2 regulates coagulation activation through endothelial tissue factor in rat haemorrhagic shock model licorice root, up-regulates manganese superoxide dismutase, catalase and paraoxonase 2 under glucose stress Putative innate immunity of antiatherogenic paraoxanase-2 via STAT5 signal transduction in HIV-1 infection of hematopoietic TF-1 cells and in SCID-hu mice Acknowledgments FP thanks the University Grant Commission, India, for junior research fellowship.